Format

Send to

Choose Destination
Leuk Res. 2009 Sep;33(9):1156-7. doi: 10.1016/j.leukres.2009.04.011. Epub 2009 May 17.

Hypothesis: how do JAK2-inhibitors work in myelofibrosis.

Author information

1
Mayo Clinic, Scottsdale, AZ, USA.

Abstract

JAK2-inhibitors rapidly reduce spleen enlargement and clinical symptoms in persons with myelofibrosis but have little, if any, effect on the WBC, anemia, decreased platelets or bone marrow fibrosis. Also, JAK2-inhibitors are active in persons with and without the JAK2-mutation. Based on these and other data we suggest that the predominant effect of JAK2-inhibitors in persons with myelofibrosis is on normal rather than the abnormal clones.

PMID:
19450878
DOI:
10.1016/j.leukres.2009.04.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center